SCHEMBL19781773

SCHEMBL19781773

N#Cc1cccc(S)c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.41
ESR2 Q92731 1/20 0.39
TSHR P16473 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
KMT2A Q03164 1/20 0.37
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
AR P10275 2/20 0.35
TRPV4 Q9HBA0 3/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MCL1 Q07820 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3032522 0.83 CXCR2 (0.47) CXCR2ESR2TSHRKDM4EMEN1
SCHEMBL491433 0.76 ALDH1A1 (0.52) CXCR2ESR2TSHRKDM4EMEN1
SCHEMBL1966377 0.76 TSHR (0.41) ESR2TSHRKDM4EALDH1A1CA1
SCHEMBL21173600 0.76 ESR2 (0.52) CXCR2ESR2TSHRKDM4EMEN1
SCHEMBL31609682 0.76 ALDH1A1 (0.52) CXCR2ESR2TSHRKDM4EMEN1
SCHEMBL30338255 0.75
SCHEMBL100731 0.75
Lithium SCHEMBL31158051 0.74 ALDH1A1 (0.50) CXCR2ESR2TSHRKDM4EMEN1
SCHEMBL4076853 0.74 ALDH1A1 (0.50) CXCR2ESR2TSHRKDM4EMEN1
SCHEMBL3074213 0.74 MAOA (0.45) TSHRKDM4EMEN1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597377-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-24 US disclosed
WO-2018013676-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10597377-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 CXCR2 3096/4885ESR2 635/4885TSHR 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.